Longboard pharmaceuticals announces positive interim results from the open-label extension (ole) of the phase 1b/2a pacific study evaluating bexicaserin in participants with developmental and epileptic encephalopathies (dees)

La jolla, calif.--(business wire)---- $lbph #5ht2--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive interim results from its ongoing 52-week open-label extension of the pacific study evaluating bexicaserin (lp352) in participants ages 12-65 years old with developmental and epileptic encephalopathies. “we are thrilled to see a sustained, durable response in seizure.
LBPH Ratings Summary
LBPH Quant Ranking